| HS Code | 420647 |
| Productname | Grass Carp Haemorrhagic Disease Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Producttype | Inactivated veterinary vaccine API |
| Targetdisease | Grass carp haemorrhagic disease |
| Activeingredient | Inactivated grass carp haemorrhagic disease virus (GCHDV) antigen |
| Inactivationmethod | Chemically inactivated using formalin or binary ethylenimine |
| Veterinarygrade | Yes |
| Intendedspecies | Grass carp (Ctenopharyngodon idella) |
| Dosageforms | Tablets, injections, capsules, powders, granules, premix, solutions |
| Routeofadministration | Oral, injection, or as per formulated veterinary dosage form |
| Storagecondition | Store at 2-8°C, protected from light and freezing |
| Shelflife | 12 months from date of manufacture |
| Immunogenicity | Induces protective immunity against grass carp haemorrhagic disease virus |
| Adjuvant | May contain veterinary-approved adjuvant to enhance immune response |
As an accredited Grass Carp Haemorrhagic Disease Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Veterinary grade inactivated vaccine API supplied in 100 mL sterile glass vials, sealed, for manufacturing dosage forms. |
| Container Loading (20′ FCL) | This 20′ FCL shipment contains veterinary vaccine API, packaged in temperature-controlled, sealed containers, loaded on pallets for safe, compliant transport. |
| Shipping | Ship under strict temperature control at 2–8°C, protected from light and freezing. Use validated insulated containers with refrigerant packs and temperature loggers. Comply with veterinary biological shipping regulations, include Material Safety Data Sheets, and label as biological substance, Category B. Ensure prompt delivery to maintain product stability and efficacy. |
| Storage | Store at 2–8°C (36–46°F), protected from light and moisture. Do not freeze. Keep in original, tightly sealed container in a well-ventilated area, away from children, food, and animals. Follow label directions; avoid temperature fluctuations during handling and transport. Dispose of unused or expired material according to veterinary waste regulations. |
| Shelf Life | Shelf life is typically 18-24 months when stored refrigerated at 2-8°C, protected from light, per stability studies. |
Formulation of a water-in-oil injectable emulsion begins with an aqueous antigen phase containing the inactivated Grass Carp Haemorrhagic Disease Vaccine API diluted to 108.5–109.5 TCID50 equivalents per mL before emulsification. The antigen phase is combined with light mineral oil at 48–60% v/v, sorbitan monooleate at 3.5–6.0% v/v, and polysorbate 80 at 0.5–1.5% v/v; the inactivated antigen concentrate itself occupies 30–45% v/v of the final emulsion. Residual formaldehyde is controlled at ≤0.2% w/v to limit injection-site myositis in fingerlings. Batch production uses a rotor-stator high-shear homogeniser with tip speed 6–12 m/s at 5,000–8,000 rpm for 15–25 min; temperature is held at 20–25°C because excursions above 30°C can reduce emulsion viscosity stability and accelerate antigen degradation. Post-homogenisation droplet size is verified by laser diffraction with Dv90 maintained at 5–15 μm; larger Dv90 values correlate with increased injection-site reactogenicity in field safety trials. Apparent viscosity at 20°C is 200–800 mPa·s, which is compatible with manual syringes but not with high-speed multi-head injection lines. Compliance during release includes sterility per USP <71>, bacterial endotoxin limits per USP <85>, target animal safety according to VICH GL44, and killed virus vaccine requirements under 9 CFR 113.200. Terminal finished product type: water-in-oil injectable emulsion, filled at 100 mL multi-dose vials; intraperitoneal dose is 0.2–0.3 mL per fish for fingerlings of 10–50 g.
Low-viscosity oil-in-water emulsions are specified when automated intraperitoneal injection lines require flowable product at 4–8°C without pre-warming. In this configuration the inactivated antigen phase is increased to 65–80% v/v, light mineral oil is reduced to 10–20% v/v, polysorbate 80 is used at 1.0–3.0% w/v, and sorbitan oleate at 0.5–1.0% w/v as co-emulsifier; final antigen titre is adjusted to 108.0–109.0 TCID50 equivalents per mL. The production route avoids rotor-stator high-shear after coarse emulsification because prolonged high shear can cause droplet coalescence and heat generation above 30°C. Instead, a propeller mixer at 300–800 rpm forms a coarse dispersion, followed by microfluidisation at 10,000–20,000 psi for one to two passes; the resulting droplet size Dv90 is 1–3 μm. Apparent viscosity at 20°C is 50–150 mPa·s, permitting use in multi-head injection machines with 0.6 mm needles. Compliance for the diluted aqueous phase includes sterility testing per Ph. Eur. 2.6.1, bacterial endotoxin limits per Ph. Eur. 2.6.14, and target animal safety evaluation according to VICH GL44. Terminal finished product type: oil-in-water injectable emulsion, 250 mL HDPE bottles for automated vaccination campaigns; injection volume is 0.2 mL per fish.
| Formulation parameter | Water-in-oil injectable emulsion | Oil-in-water injectable emulsion |
|---|---|---|
| Antigen phase addition | 30–45% v/v | 65–80% v/v |
| Oil phase addition | 48–60% v/v | 10–20% v/v |
| Emulsifier system | 4.0–7.5% w/v | 1.5–4.0% w/v |
| Droplet size Dv90 | 5–15 μm | 1–3 μm |
| Apparent viscosity at 20°C | 200–800 mPa·s | 50–150 mPa·s |
| Intraperitoneal injection volume | 0.2–0.3 mL | 0.2 mL |
Autogenous production campaigns using a qualified inactivated antigen concentrate are performed in 50–200 L single-use mixing bags when regional GCRV isolates show antigenic drift from the reference strain and no licensed strain-complete vaccine is available. The antigen concentrate is added at 50–80% v/v, aluminium hydroxide gel at 10–15% v/v, sterile phosphate-buffered saline pH 7.2 q.s., and thiomersal at 0.01% w/v only when multi-dose vials are used. Adsorption is carried out at 4°C for 12–16 h with gentle agitation at 100–200 rpm; the mixing speed is kept below 200 rpm to avoid aluminium gel flocculation and inconsistent antigen presentation. Failure mode observed in scale-down campaigns is gel settling when agitation stops for more than 2 h; therefore continuous low-shear mixing is maintained through filling. Potency is confirmed by virus neutralisation against the local isolate, and sterility is retested after final filling per USP <71>. Autogenous biologics are handled according to 9 CFR 113.113 where applicable, with additional national or regional autogenous vaccine oversight; published data for this specific configuration is limited, so batch release relies on in-house virus neutralisation, sterility, and endotoxin data. Terminal finished product type: autogenous injectable suspension, 50 mL vials.
| Compliance parameter | Standard designation |
|---|---|
| Sterility | USP <71>, Ph. Eur. 2.6.1 |
| Bacterial endotoxin | USP <85>, Ph. Eur. 2.6.14 |
| Target animal safety | VICH GL44 |
| Killed virus vaccine requirements | 9 CFR 113.200 |
| Autogenous biologics | 9 CFR 113.113 |
| Veterinary vaccine safety evaluation | Ph. Eur. 5.2.6 |
Where broodstock immunization is performed during pre-spawning quarantine, an aluminium hydroxide-adjuvanted suspension is selected because it produces fewer injection-site granulomas than mineral oil emulsions in fish held for breeding. The antigen concentrate is added at 40–60% v/v, aluminium hydroxide gel at 20–30% v/v, and final aluminium content is adjusted to 0.3–0.8 mg per 0.5 mL dose; pH is maintained at 6.8–7.4 using phosphate buffer. Aseptic blending is performed at 150 rpm for 6–12 h at 4°C; the suspension is not passed through high-shear equipment because aluminium gel flocculation can reduce antigen adsorption and cause sedimentation in storage. Sterility is verified per USP <71>, bacterial endotoxin per USP <85>, and aluminium content by inductively coupled plasma mass spectrometry. Terminal finished product type: aqueous suspension for intraperitoneal injection, 500 mL PVC bags.
Bulk inactivated antigen solution is used as an intermediate by licensed veterinary biologics manufacturers that blend multiple antigens or apply their own adjuvant platforms. The concentrate is added at 20–60% v/v of the final formulation depending on adjuvant load, with pH maintained at 7.0–7.6 and residual formaldehyde kept at ≤0.2% w/v. Downstream processing includes clarification through a 0.45 μm capsule filter only when particulate load exceeds specification; terminal sterile filtration below 0.22 μm is not recommended because antigen aggregates can lose titre during passage. Blending with adjuvants is performed in 50 L single-use bags with magnetic impeller agitation at 80–150 rpm, and the resulting liquid is held at 2–8°C before filling. Compliance for the bulk intermediate includes EU GMP Annex 2 provisions for biological active substances, sterility testing per USP <71>, endotoxin testing per USP <85>, and safety evaluation per Ph. Eur. 5.2.6. The powder, granule, tablet, capsule and premix physical forms are not validated for oral administration of this inactivated reovirus antigen; published data for these configurations is limited and does not support consistent systemic protection. Terminal finished product type: concentrated antigen solution intermediate for injectable emulsion or suspension.
Competitive Grass Carp Haemorrhagic Disease Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Grass Carp Haemorrhagic Disease Vaccine, Inactivated Veterinary Grade API is supplied as a killed whole-virus antigen intermediate derived from cell-culture-propagated grass carp reovirus (GCRV). The material is not a ready-to-administer vaccine: it contains no adjuvant, preservative, or final isotonic diluent, and it is intended for further manufacture by a licensed veterinary vaccine facility into injections, solutions, powders, premixes, granules, capsules, or tablets. No model code is printed in the current technical description, so a purchaser should require the certificate of analysis to record master seed lot, working seed lot, bioreactor campaign number, inactivation batch number, and lyophilization cycle identifier. For refrigerated lyophilized material, long-term storage is commonly specified at 2–8 °C; frozen liquid intermediates may require ≤ -15 °C. The presence of multiple dosage form labels does not imply that every route is approved by a pharmacopoeial monograph. Injectable and solution formats align with parenteral veterinary vaccine use, whereas tablet and capsule formats require product-specific proof that the antigen remains immunogenic after enteric exposure and compression.
A bulk inactivated antigen differs from a finished injection in three essential aspects. First, the final injection contains an adjuvant such as aluminum hydroxide or a mineral-oil emulsion, an isotonic diluent, and often a preservative; the API is supplied without these components. Second, the finished injection is released as a sterile, adjuvanted dose form with a defined volume and potency per fish, whereas the API is released on mass or titre basis. Third, the final injection must be produced under aseptic conditions in an ISO 14644-1 Class 5 cleanroom and must pass sterility testing by Ph. Eur. 2.6.1 or USP <71> after formulation. The API itself may be sterile or low-bioburden, but the receiving manufacturer must verify that downstream filtration, mixing, and filling do not reduce antigen content or introduce endotoxin. A recommended control matrix is shown in Table 1.
| Attribute | Reference method | Critical control point |
|---|---|---|
| Sterility | Ph. Eur. 2.6.1, USP <71> | Aseptic processing in ISO 14644-1 Class 5 cleanroom |
| Bacterial endotoxins | Ph. Eur. 2.6.14, USP <85> | Product-specific limit expressed as endotoxin units per final dose |
| Residual moisture | Ph. Eur. 2.2.32, USP <731> | Lyophilized veterinary biologicals commonly set ≤ 3.0% w/w |
| pH after rehydration | Ph. Eur. 2.2.3, USP <791> | 7.0–7.8 in sterile phosphate-buffered saline |
| Virus titre | TCID50 on permissive cell line, RT-qPCR genome copies | Release titre must be tied to target dose and potency challenge model |
| Residual inactivation agent | HPLC with post-derivatization detection | Product-specific limit; no added excipient should interfere with derivatization |
Inactivation kinetics are established during process validation using a stirred inactivation reactor. Formaldehyde at 0.025%–0.1% or binary ethylenimine at controlled temperature is commonly employed; the manufacturer must demonstrate a logarithmic reduction of infectivity exceeding the theoretical virus titre over a defined time. Residual formaldehyde is quantified by HPLC after derivatization with 2,4-dinitrophenylhydrazine. Virus harvest from cell culture is clarified by depth filtration before inactivation. Lyophilization is performed in a shelf freeze-dryer with product temperature below the formulation collapse temperature; primary drying is commonly below -30 °C, but published data for this specific inactivated GCRV API are limited. The resulting cake is assessed for appearance, residual moisture, and reconstitution time. Recombinant subunit GCRV vaccines based on VP4 or VP7 proteins do not require inactivation, but the inactivated whole-virus API retains the full capsid protein set and may present conformational epitopes lost in subunit preparations. This difference should be confirmed by a virus neutralization assay rather than inferred from total protein content.
For dry dosage forms, the API is typically blended with mannitol, trehalose, or microcrystalline cellulose in a low-shear tumble blender. Aqueous granulation is not recommended because shear and free water can induce antigen aggregation; if granulation is unavoidable, a fluid-bed granulator with inlet air temperature below 35 °C should be qualified. Tablet compression requires an instrumented rotary tablet press; compression force and dwell time should be limited to avoid protein film formation and loss of TCID50. Capsule filling may use a low-speed tamping or dosator machine, but hygroscopic carriers must be pre-dried at RH < 60%. These operations are not described in a public pharmacopoeial monograph for fish vaccine APIs; published data for tablet and capsule formulations of inactivated GCRV are limited. For injection, the lyophilized antigen is reconstituted in sterile phosphate-buffered saline at pH 7.0–7.8 and then emulsified with a suitable mineral-oil or aluminum hydroxide adjuvant using a rotor-stator homogenizer. The adjuvant selection changes the final immunogenicity and safety profile; the API itself does not specify the adjuvant type.
On manufacturing lines with twin-screw continuous blending or instrumented rotary tablet presses, the first observed failure mode is aggregation rather than chemical degradation. Batch-to-batch variance in lyophilized cake humidity, reconstitution time, and TCID50 can occur when freeze-dryer shelf temperature is nonuniform; tray mapping with Type T thermocouples is required to document shelf uniformity. Avoid combination with zeolite or bentonite carriers in premix because cation exchange and residual moisture can strip antigen from the particulate surface. If feed pelleting is used, the antigen-bearing premix must be applied post-pelleting, because conventional steam conditioning temperatures above 70 °C denature viral capsid proteins. For capsule and tablet products, gastric inactivation is expected unless enteric coating is validated by USP <711> dissolution or a simulated gastric fluid challenge. The API should be assigned a model distinguishing the virus strain and inactivation process; if no model is indicated, the buyer must require seed lot documentation and a certificate of analysis before any formulation work.
| Feature | Inactivated whole-virus API | Live attenuated GCRV vaccine | Recombinant subunit antigen |
|---|---|---|---|
| Reversion to virulence | Absent after validated inactivation; each inactivation lot must show no residual infectivity | Low but requires serial passage and genetic stability monitoring | Absent |
| Adjuvant dependence | Not included; final manufacturer selects adjuvant | Often not required | Requires adjuvant or conjugate |
| Dosage form compatibility | Freeze-dried or frozen bulk; can be dry-blended if water activity controlled | Liquid live virus; cold chain, more labile | Can be lyophilized or emulsified |
| Critical potency test | Antigen content by ELISA or in vivo virus neutralization after vaccination | TCID50 plaque assay | Protein content and antigenicity ELISA |
| Main process risk | Residual formaldehyde, incomplete inactivation, aggregate formation during drying | Temperature abuse, reversion, shedding | Low yield, conformational epitope loss |
Regulatory submissions for the listed oral formats should not rely solely on antigen mass per gram. The applicant should demonstrate that the antigen remains immunoreactive after exposure to the intended granulation, compression, drying, and coating steps, and that the final oral dose produces a measurable neutralizing antibody response or survival benefit in target grass carp under challenge conditions. Directive 2001/82/EC and EU GMP Annex 2 govern veterinary medicinal products and biological active substances, but no harmonized VICH efficacy guideline specifically covers fish oral vaccines; therefore, national requirements and applicable WOAH aquatic animal health standards must be consulted. The API is not compatible with reducing sugars during drying because Maillard adducts can mask neutralizing epitopes. Sucrose is not recommended as a primary bulking agent if the lyophilized material will be exposed to repeated short-term temperature excursions above 25 °C, because residual moisture can generate a mobile amorphous phase. Any batch failing residual moisture, sterility, or endotoxin criteria must be quarantined and cannot be reworked by re-lyophilization without product-specific revalidation.
